HOME
KOREAN
About Us
Company Overview
BOD and SAB
History
Contact us
R&D
Core Technology
Products
Services
Investor Relations
Stock Price Information
Under Construction
Media
Notices
Press Release
PR Video
Careers
Ideal Man
Careers Guide
Antibody Therapeutics for Life
Notices
Press Release
PR Video
Notices
No
Title
Written by
Written date
Inquire
46
PharmAbcine, a clinical stage immune-oncology company, today announced that Dr. Jin-San Yoo, Chairman and Chief Executive Officer of PharmAbcine is invited to present at the 73rd Annual Conference of KAOBS.
°ü¸®ÀÚ
2019-01-14
55
45
PharmAbcine, a clinical stage immune-oncology company, today announced that Dr. Jin-San Yoo, Chairman and Chief Executive Officer of PharmAbcine has presented as invited speaker at GBC 2018 on June 26-29, 2018
°ü¸®ÀÚ
2019-01-14
53
44
PharmAbcine, a clinical stage immune-oncology company, today announced that Dr. Jin-San Yoo, Chairman and Chief Executive Officer of PharmAbcine is invited as a chairman of the session of the antibody therapeutics at BIOPLUS 2018 on September 6-9, 2018.
°ü¸®ÀÚ
2019-01-14
56
43
PharmAbcine, a clinical stage immune-oncology company, today announced that Dr. Jin-San Yoo, Chairman and Chief Executive Officer of PharmAbcine is invited to give a presentation as a speaker and panelist at AFOB SUMMER FORUM 2018
°ü¸®ÀÚ
2019-01-14
54
42
PharmAbcine, a clinical stage immune-oncology company, today announced that Dr. Jin-San Yoo, Chairman and Chief Executive Officer of PharmAbcine is attending ASCO 2018.
°ü¸®ÀÚ
2019-01-14
62
41
PharmAbcine, a clinical stage immune-oncology company, today announced that Dr. Jin-San Yoo, Chairman and Chief Executive Officer of PharmAbcine and Dr. Sung Woo Kim, Head of Business Development are attending BIO 2018.
°ü¸®ÀÚ
2019-01-14
55
40
PharmAbcine, a clinical stage immune-oncology company, today announced that Dr. Jin-San Yoo, Chairman and Chief Executive Officer of PharmAbcine is invited to present at the company presentation session at BIO 2018.
°ü¸®ÀÚ
2019-01-14
52
39
PharmAbcine Announces FDA Orphan Drug Designation Granted to TTAC-0001 for Glioblastoma Multiforme.
°ü¸®ÀÚ
2019-01-14
53
38
`` Evaluation of drug mechanism and efficacy of a novel anti-angiogenic agent, TTAC-0001, using multi-modality bioimaging in a mouse breast cancer orthotopic model`` is now indexed on PubMed.
°ü¸®ÀÚ
2019-01-14
50
37
``Preclinical pharmacokinetics, interspecies scaling, and pharmacokinetics of a Phase I clinical trial of TTAC-0001, a fully human monoclonal antibody against vascular endothelial growth factor 2`` is now indexed on PubMed.
°ü¸®ÀÚ
2019-01-14
49
1
2
3
4
5
6
--search--
Title
Written by
content